The aim of this study was to comprehend the risk of IV t-PA treatment in patients with intracranial tumor and cavernoma, in order to facilitate the clinician’s burden of taking the decision in this common but insufficiently respected constellation. The gene discussed is PLAT; the disease is cavernous hemangioma.